{"id":2432,"date":"2016-12-01T12:00:00","date_gmt":"2016-12-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/kardiovaskulaere-nebenwirkungen-und-komplikationen-bei-onkologischen-therapien"},"modified":"2022-03-17T14:13:29","modified_gmt":"2022-03-17T13:13:29","slug":"kardiovaskulaere-nebenwirkungen-und-komplikationen-bei-onkologischen-therapien","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/kardiovaskulaere-nebenwirkungen-und-komplikationen-bei-onkologischen-therapien","title":{"rendered":"Kardiovaskul\u00e4re Nebenwirkungen und Komplikationen bei onkologischen Therapien"},"content":{"rendered":"<p>Zusammenfassung: Neben den bekannten toxischen Wirkungen von Anthrazyklinen und Trastuzumab auf die Funktion des linken Ventrikels werden in der Onkologie sowohl Medikamente als auch Radiotherapien angewendet, die Sch\u00e4den an Herzklappen und Arterien (koronar, zerebral, peripher) und dem Myokard sowie thromboembolische Komplikationen verursachen k\u00f6nnen. Au\u00dfer den heute nur teilweise bekannten Nebenwirkungen neuer onkologischer Wirkstoffe (z.B. &#8222;zielgerichtete&#8220; [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Neben den bekannten toxischen Wirkungen von Anthrazyklinen und Trastuzumab auf die Funktion des linken Ventrikels werden in der Onkologie sowohl Medikamente als auch Radiotherapien angewendet, die Sch\u00e4den an Herzklappen und Arterien (koronar, zerebral, peripher) und dem Myokard sowie thromboembolische Komplikationen verursachen k\u00f6nnen. Au\u00dfer den heute nur teilweise bekannten Nebenwirkungen neuer onkologischer Wirkstoffe (z.B. &#8222;zielgerichtete&#8220; [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[268,2842,684,1964,495,1967,60,1272,255,4471,61,324,1446,4665,428,1573,4801,4003,271,30,3568,2288,27,2803,1962,2941,274,703,706,2155,804,71,180,519,187,68,325,1991,707,834,2845,1508,222,498,3098,3937,4803,202,69,1589,257,279,65,256,2805,3258,226,2246,4748,2807,4802,4804,514,198,267,3036,183,1728,56,2929,263,936,1961,54,51,1884,1302,803,802,254,253,3298,4800,4799,55,262,264],"class_list":["post-2432","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-5-fluorouracil","tag-afatinib","tag-akutes-koronarsyndrom","tag-alkylanzien","tag-angina-pectoris","tag-anthrazykline","tag-apoplektischer-insult","tag-arteriosklerose","tag-arzneimittel","tag-axitinib","tag-beinvenenthrombose","tag-blutdruck","tag-bosutinib","tag-cabozantinib","tag-capecitabin","tag-carfilzomib","tag-checkpoint-inhibitoren","tag-chemotherapeutika","tag-chemotherapie","tag-cisplatin","tag-clofarabin","tag-crizotinib","tag-cyclophosphamid","tag-dasatinib","tag-daunorubicin","tag-dexrazoxan","tag-docetaxel","tag-doxorubicin","tag-epirubicin","tag-erlotinib","tag-gefitinib","tag-herzinfarkt","tag-herzinsuffizienz","tag-herzklappenerkrankungen","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-hypertonie","tag-ibrutinib","tag-idarubicin","tag-imatinib","tag-ipilimumab","tag-kardiotoxizitaet","tag-karzinome","tag-koronare-herzkrankheit","tag-krebs","tag-lapatinib","tag-lenvatinib","tag-long-qt-syndrom","tag-lungenembolie","tag-malignome","tag-medikamente","tag-mitoxantron","tag-myokardinfarkt","tag-nebenwirkungen","tag-nilotinib","tag-nivolumab","tag-onkologie","tag-pazopanib","tag-pembrolizumab","tag-ponatinib","tag-proteasom-hemmer","tag-proteasom-inhibitoren","tag-pulmonale-hypertonie","tag-qt-zeit-verlaengerung","tag-radiotherapie","tag-regorafenib","tag-rhythmusstoerungen","tag-ruxolitinib","tag-schlaganfall","tag-sorafenib","tag-strahlentherapie","tag-sunitinib","tag-taxane","tag-thromboembolie","tag-thrombose","tag-trastuzumab","tag-tumore","tag-tyrosinkinase-hemmer","tag-tyrosinkinase-inhibitoren","tag-uaw","tag-unerwuenschte-arzneimittelwirkungen","tag-vandetanib","tag-vascular-endothelial-growth-factor-inhibitoren","tag-vegf-inhibitoren","tag-venenthrombose","tag-zytostatika","tag-zytostatische-therapie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2432"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2432\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}